Wire · opportunities
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 July 2026 · Fusion42 review
Vera Therapeutics won FDA accelerated approval for TRUTAKNA (atacicept-vymj), the first BAFF/APRIL inhibitor for IgA nephropathy, based on 46% proteinuria reduction in Phase 3 trials. The company is launching with 82 nephrology-focused sales reps and a $425,000 annual list price, targeting 6,000 nephrologists serving ~160,000 US patients.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you sell into nephrology or rare kidney disease, Vera just opened a 6,000-doctor market that was untreated until today — and they've already hired the 82 reps and set the payer conversations. Your window to partner or sell into their launch is the next 90 days, before ORIGIN 3 confirmatory data locks the market position.
◆ Coverage
1 source · 12 Jul 2026
◆ Related on Wire
◆ Topics